A randomized phase II study of Pembrolizumab (MK-3475) as maintainance therapy in patients with unresectable stage III non-small cell lung cancer treated with definitive chemo-radiotherapy (MP-LALC- Maintainance Pembrolizumab in Locally Advanced Lung Cancer).

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514701-57-01

Acronym

MP-LALC

Enrollment

126

Registered

2024-12-16

Start date

Unknown

Completion date

Unknown

Last updated

2025-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non Small Cell Lung Cancer

Brief summary

Median overall survival (OS) time

Detailed description

Overall survival (OS) defined as the time from randomization to death or last follow-up, Progression Free Survival (PFS) intended as the time from randomization to disease progression or death, Overall Response Rate (ORR)

Interventions

DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Median overall survival (OS) time	—

Secondary

Measure	Time frame
Overall survival (OS) defined as the time from randomization to death or last follow-up, Progression Free Survival (PFS) intended as the time from randomization to disease progression or death, Overall Response Rate (ORR)	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026